Alexion Pharma Germany GmbH, a subsidiary of Alexion Pharmaceuticals, Inc., is a leading biopharmaceutical company headquartered in Germany. Established in 1992, Alexion has made significant strides in the field of rare diseases, focusing on innovative therapies that address unmet medical needs. The company operates primarily in Europe, with a strong presence in Germany, where it develops and commercialises life-changing treatments. Specialising in complement inhibition, Alexion is renowned for its flagship products, including Soliris and Ultomiris, which are designed to treat conditions such as paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome. These therapies are distinguished by their ability to provide long-lasting efficacy and improve patients' quality of life. With a robust market position, Alexion Pharma Germany GmbH continues to be a pioneer in the biopharmaceutical industry, committed to advancing healthcare solutions for patients with rare and complex diseases.
We don't have data for Alexion Pharma Germany GmbH, but we can show you information about their parent organization instead.
View parent company